Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Share-based Compensation (2016 - 2025)

Angiodynamics (ANGO) has disclosed Share-based Compensation for 16 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 14.36% year-over-year to $2.9 million, compared with a TTM value of $11.4 million through Nov 2025, up 11.32%, and an annual FY2025 reading of $9.8 million, down 7.19% over the prior year.
  • Share-based Compensation was $2.9 million for Q4 2025 at Angiodynamics, down from $4.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.5 million in Q3 2025 and bottomed at $1.6 million in Q2 2025.
  • Average Share-based Compensation over 5 years is $2.7 million, with a median of $2.6 million recorded in 2024.
  • The sharpest move saw Share-based Compensation plummeted 43.97% in 2023, then surged 44.87% in 2024.
  • Year by year, Share-based Compensation stood at $3.0 million in 2021, then rose by 11.37% to $3.4 million in 2022, then crashed by 43.97% to $1.9 million in 2023, then skyrocketed by 34.68% to $2.5 million in 2024, then rose by 14.36% to $2.9 million in 2025.
  • Business Quant data shows Share-based Compensation for ANGO at $2.9 million in Q4 2025, $4.5 million in Q3 2025, and $1.6 million in Q2 2025.